A meta-analysis of 31 randomized controlled trials demonstrated a 25% relative risk reduction in serious AF events among patients treated with SGLT-2 inhibitors compared with placebo or other glucose-lowering agents [108]. Here, SLC5A2 is linked to atrial fibrillation.